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Objectives This study sought to compare catheter ablation with rate control for persistent atrial fibrillation (AF) in heart fail-
ure (HF).
Background The optimal therapy for AF in HF is unclear. Drug-based rhythm control has not proved clinically beneficial. Cath-
eter ablation improves cardiac function in patients with HF, but impact on physiological performance has not
been formally evaluated in a randomized trial.
Methods In a randomized, open-label, blinded-endpoint clinical trial, adults with symptomatic HF, radionuclide left ventric-
ular ejection fraction (EF) 35%, and persistent AF were assigned to undergo catheter ablation or rate control.
Primary outcome was 12-month change in peak oxygen consumption. Secondary endpoints were quality of life,
B-type natriuretic peptide, 6-min walk distance, and EF. Results were analyzed by intention-to-treat.
Results Fifty-two patients (age 63  9 years, EF 24  8%) were randomized, 26 each to ablation and rate control. At 12
months, 88% of ablation patients maintained sinus rhythm (single-procedure success 68%). Under rate control,
rate criteria were achieved in 96%. The primary endpoint, peak oxygen consumption, significantly increased in
the ablation arm compared with rate control (difference 3.07 ml/kg/min, 95% confidence interval: 0.56 to
5.59, p  0.018). The change was not evident at 3 months (0.79 ml/kg/min, 95% confidence interval: 1.01
to 2.60, p  0.38). Ablation improved Minnesota score (p  0.019) and B-type natriuretic peptide (p  0.045)
and showed nonsignificant trends toward improved 6-min walk distance (p  0.095) and EF (p  0.055).
Conclusions This first randomized trial of ablation versus rate control to focus on objective exercise performance in AF and HF
shows significant benefit from ablation, a strategy that also improves symptoms and neurohormonal status. The ef-
fects develop over 12 months, consistent with progressive amelioration of the HF syndrome. (A Randomised Trial to
Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Fail-
ure; NCT00878384) (J Am Coll Cardiol 2013;61:1894–903) © 2013 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.069Atrial fibrillation (AF), the commonest arrhythmia in hu-
mans, causes a substantial burden of morbidity on patients
and cost on healthcare systems. In patients with heart failure
(HF), AF becomes more common and imposes greater
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2012, accepted January 23, 2013.burdens (1–3). Prevalence of AF rises from 10% in mild
toward 50% in severe HF (3). Coexistence of AF with HF
is associated with increased hospital stay and mortality (4,5)
and further increases the stroke risk from AF 3-fold (6).
See page 1904
Rhythm control with antiarrhythmic drugs has not been
shown to confer benefit in randomized trials, whether in
patients with (7) or without HF (8,9). The lack of benefit
from antiarrhythmic drugs might reflect their poor (50%)
efficacy in maintaining sinus rhythm (7–9). The risk of
adverse effects might outweigh the benefits of restoring
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May 7, 2013:1894–903 Ablation Versus Rate Control for AF in HFsinus rhythm, and indeed most antiarrhythmics are contra-
indicated in HF. Nonrandomized studies of catheter abla-
tion, which might avoid such problems, have shown im-
provements in cardiac function (10–13), exercise capacity
(12), and quality of life (14) in patients with HF and AF.
We designed a clinical trial to test the ability of ablation-
based rhythm control to improve objective cardiovascular
function in patients with HF and persistent AF. Impair-
ment of exercise intolerance is both a hallmark symptom of
HF and an important indicator of long-term survival. Given
that peak oxygen consumption (VO2) is a strong prognostic
ndicator (15–17), we chose a change in peak VO2 as the
rimary endpoint. For the control arm we chose the
ontemporary standard-of-care for persistent AF in HF, a
igorous rate-control strategy that is at least noninferior to
harmacological rhythm control (7).
ethods
atients. The enrollment criteria were 18 to 80 years of
ge, persistent AF (7 days), symptomatic HF (New York
eart Association functional class II to IV) on optimal HF
herapy, and left ventricular ejection fraction (EF) 35%.
xclusion criteria included cardiovascular implantable elec-
ronic device insertion or cerebrovascular event within 6
onths; coronary revascularization or atrioventricular nodal
blation within 3 months; reversible causes of AF or HF
ncluding thyroid dysfunction, alcohol, primary valvular
isease, or recent major surgery; prior heart transplant or on
rgent transplant waiting list; pregnancy; active malignancy;
evere renal impairment; single chamber pacemaker and
trioventricular block; and contraindications to general an-
sthesia or oral anticoagulation. Optimal HF therapy was
efined as taking or having tried angiotensin-converting
nzyme inhibitor (or angiotensin blocker), beta-blocker, and
ther therapy as recommended by their HF specialist;
aving had therapy for 1 month; and symptoms for 3
onths. Prior failure of rhythm control by electrical or
harmacological cardioversion was not a prerequisite for
nrollment, and no pre-enrollment rate-control criteria were
pecified.
The study, approved by the local research ethics commit-
ee in December 2008, was conducted at Royal Brompton
nd Harefield hospitals between April 2009 and June 2012.
atients were consecutively screened and enrolled after
eferral from cardiology services based locally and at linked
eferring hospitals. All patients provided written informed
onsent.
aseline assessment. Baseline assessment comprised his-
ory, physical examination, blood tests including B-type
atriuretic peptide (BNP), radionuclide ventriculography,
ardiopulmonary exercise testing, 2-dimensional echocardi-
graphy, Minnesota Living with Heart Failure Question-
aire (MLHFQ), 6-min walk test, and 24-h Holter elec-
rocardiogram (ECG). pCardiopulmonary treadmill
xercise testing was performed
ith the modified Bruce proto-
ol. Peak VO2 (ml/kg/min) was
efined as the mean of the high-
st 2 consecutive values of 15-s
verages of VO2. The ventila-
ion/carbon dioxide (ventilatory
fficiency) slope was obtained by
inear regression analysis of the
ata acquired throughout the en-
ire period of exercise (16,18).
Because ejection fraction var-
es between beats in AF, we
voided methods that involve se-
ecting beats for EF calculation
19). We chose radionuclide ventriculography, which sys-
ematically averages across hundreds of heartbeats.
andomization and masking. After baseline investiga-
ions, eligible patients underwent 1:1 randomization by
omputer-generated sequence, stratified for age (above and
elow 50 years) and known atrioventricular block. The study
as open-label; however, those conducting cardiopulmo-
ary exercise testing, blood assays, and imaging analysis
ere blinded to randomization. The VO2 results were
nvestigator-blinded until completion of follow-up.
ate control. Patients received pharmacological therapy
beta-blockers and/or digoxin) targeted to achieve a mean
eart rate (assessed by apical auscultation over 30 s) 80
eats/min at rest before and 110 beats/min after a 6-min
alk (7,8). If rate-control criteria were not met at baseline
r during follow-up, patients re-attended at 4-week inter-
als for repeat assessment and adjustment of drug therapy
ntil targets were achieved. In patients with pacemakers, if
he base rate (80 beats/min) was not exceeded, no addi-
ional medication was prescribed for rate control. Atrioven-
ricular node ablation and pacing was not adopted as a
rotocol, because it had just been reported to be inferior to
ulmonary vein isolation (20).
atheter ablation. The procedure was performed under
eneral anesthesia. Transesophageal echocardiography was
erformed to exclude left atrial thrombus and to guide
ransseptal puncture. Patients were heparinized to maintain
he activated clotting time over 300 s. Atrial anatomy was
econstructed with the NavX mapping system with an
FocusII catheter (St. Jude Medical, St. Paul, Minnesota).
adiofrequency ablation was performed with a 3.5-mm
rrigated-tip catheter (ThermoCool, Biosense Webster, Di-
mond Bar, California) and comprised the following step-
ise strategy: 1) pulmonary-vein isolation; 2) linear ablation
t the left atrial roof and mitral isthmus; and 3) ablation of
eft atrial complex fractionated electrograms guided by
igh-density multipolar mapping as previously described
21). If atrial tachycardia occurred, the protocol was termi-
ated, and the tachycardia was mapped and ablated. If AF
Abbreviations
and Acronyms
AF  atrial fibrillation
BNP  B-type natriuretic
peptide
CI  confidence interval
ECG  electrocardiogram
EF  ejection fraction
HF  heart failure
LA  left atrium/atrial
PVI  pulmonary vein
isolation
VO2  peak oxygen
consumptionersisted, sinus rhythm was restored by external cardiover-
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Ablation Versus Rate Control for AF in HF May 7, 2013:1894–903sion, followed by cavotricuspid isthmus ablation. All linear
lesions were checked, and further ablation was performed as
required to achieve block.
During a 2-month blanking period post-ablation, recur-
rent sustained atrial arrhythmia was treated by electrical
cardioversion. Antiarrhythmic drugs other than non-sotalol
beta-blockers were stopped post-ablation unless there was a
separate indication, such as ventricular arrhythmias, but
could be used if required within the blanking period.
Those who developed further atrial arrhythmias after
blanking were offered a second ablation procedure. A
maximum of three ablations could be performed during
the study period.
Follow-up and endpoints. Patients were followed up at 3,
, and 12 months; this commenced on the date of the first
rocedure in the ablation group and from the date of
andomization (including medication adjustment) in the
ate-control group. The primary endpoint, peak VO2, was
defined at 12 months and also measured at 3 months. The
secondary endpoints LHFQ score, BNP, and 6-min walk
distance were defined at 3, 6, and 12 months; radionuclide
EF was only re-measured at 12 months to minimize radiation
(NCT00878384). Freedom from atrial arrhythmia after
ablation was assessed by ECG rhythm documentation at
6 to 8 weeks and all follow-ups, plus 48-h ambulatory
monitoring at 6 and 12 months. Patients with implanted
devices had additional arrhythmia log interrogation at
follow-up. Any post-blanking recurrence of atrial ar-
rhythmia 30 s constituted procedural failure (22).
Bi-atrial areas were measured by transthoracic echocar-
diography (apical 4-chamber view) at baseline and at 6
and at 12 months.
Sample size calculation. We designed the study so that it
would be able to detect a change of 2 ml/kg/min in a sample
whose SD of difference between successive VO2 measure-
ents was 2.5 ml/kg/min, with 2-sided alpha 0.05, power of
0%, comparing ablation with rate control. The number of
atients required was 25 in each group.
tatistical analysis. Continuous baseline variables are pre-
ented as mean SD. Categorical variables are presented as
requency/percentage and compared with the Fisher’s exact
r the chi-square test. Outcomes were assessed, on an
ntention-to-treat basis, by independent group comparison
f absolute changes from baseline. Parametric data were
nalyzed by the Student t test and represented as mean and
5% confidence interval (CI); nonparametric/ordinal data
ere analyzed by the Mann-Whitney U test and repre-
ented as median and interquartile range. A 2-sided p 
.05 was considered statistically significant. No correction
as made for assessments made at multiple time points.
rrhythmia-free survival was analyzed by Kaplan-Meier
ethod. All calculations were performed with SPSS (ver-
ion 20, SPSS, Chicago, Illinois) and endpoint graphs were
onstructed in R (23). 0esults
total of 101 patients were referred for participation, and
5 attended for baseline assessment. Fifty-two patients were
andomized, 26 patients to each arm (Fig. 1). Baseline
haracteristics are summarized in Table 1. One patient in
he ablation arm withdrew consent for ablation and contin-
ed existing therapy; 1 patient in the rate-control arm
equested and underwent ablation after 4 months; both were
nalyzed by intention to treat. One patient in the ablation
rm—with chronic lung disease, dilated cardiomyopathy,
nd a biventricular pacemaker-defibrillator in-situ—died 11
onths post-ablation due to progressive cardio-renal fail-
re. Device interrogation showed no AF recurrence.
rimary endpoint. At 12 months peak VO2 had increased
y 2.13 (0.10 to 4.36) ml/kg/min in the ablation arm,
ompared with a decrease (0.94 [2.21 to 0.32]
l/kg/min) in the rate-control arm (mean difference 3.07
l/kg/min [0.56 to 5.59], p  0.018) (Fig. 2; individual
esponses shown in Fig. 3). At 3 months there was a
onsignificant increase of VO2 in the ablation arm (mean
difference 0.79 ml/kg/min [1.01 to 2.60], p  0.38).
Secondary endpoints. The secondary endpoints are dis-
played in Figure 4. The LHFQ score improved (reduced) in
the ablation arm, compared with rate-control, nonsignifi-
cantly at 3 months (p  0.196) but significantly at 6 (p 
0.015) and 12 months: median 15.5 (interquartile range:
26.75 to 7.25) compared with 5 (16 to 9) under
rate control (p  0.019). This reflected a change from 42 
3 and 49  21 to 21  19 and 41  21 at 12 months in
he ablation and rate-control arms, respectively. The BNP
imilarly showed nonsignificant decrease at 3 months (p 
.132) but significant reduction at 6 (p  0.038) and 12
onths (p  0.045) in the ablation arm: median 124
284 to 0) pg/ml, compared with 18 (86 to 31)
g/ml for rate control. Six-min walk distance tended to
ncrease in both groups toward 6 months. At 12 months,
blation produced a nonsignificant increase (p  0.095)
median: 21 m [51 to 89 m]) compared with a
ecrease under rate control (median:10 m [73 to15 m]).
he EF significantly increased in the ablation arm from
1.5  8.3% at baseline to 32.8  14.3% at 12 months
p  0.001), a change of 10.9  11.5%. In the rate-control
rm, EF increased from 24.9  7.2% at baseline to 30.2 
.4% at 12 months (p  0.003), a change of 5.4  8.5%.
ccordingly, EF showed a nonsignificant trend toward
mprovement in the ablation arm (mean difference 5.6%,
5% CI: 0.1 to 11.3, p  0.055) compared with rate
ontrol.
ther parameters. Exercise time mirrored peak VO2 with
onsignificant change at 3 months in the ablation arm
mean difference: 54 s [31 to 139 s], p  0.205) but
ignificant improvement by 12 months (133 s [19 to 246 s],
 0.023). Ventilation/carbon dioxide slope showed a
onsignificant reduction at 3 months (3.45 [7.33 to
.44], p  0.081) and 12 months (1.68 [6.50 to 3.14],
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ventilatory anaerobic threshold was analyzed to compare
effort between groups at follow-up: a respiratory exchange
ratio 1.05 was achieved in 17 of 26 ablation versus 16 of
26 rate control at baseline (p  0.77) and 16 of 25 versus 15
of 26 at 12 months (p  0.77). In the rate control arm,
change in peak respiratory exchange ratio was0.03 0.07
at 3 months and 0.30  0.12 at 12 months. By compar-
ison, in the catheter-ablation arm the change was 0.01 
0.12 at 3 months (p  0.39) and 0.01  0.14 at 12 months
(p  0.50). Thus, there was no evidence of differential
motivation to explain the observed differences in peak VO2.
The left atrial area decreased in the ablation arm at both
6 months (mean difference compared with rate control
4.96 cm2 [7.23 to 2.68 cm2], p  0.001) and 12
onths (6.22 cm2 [9.17 to 3.27 cm2], p  0.001).
The right atrial area showed a similar decrease at 6 months
(5.44 cm2 [8.33 to 2.61 cm2], p  0.001) but not at
2 months (2.62 cm2 [5.99 to 0.74 cm2], p  0.12)
Figure 1 Consort Diagram for ARC-HF
*No 6- or 12-month data for 1 patient who died before final review. AF  atrial fib
trol in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure; GA
fraction.Fig. 5).ate control. At baseline, rate-control criteria were met in
4 of 26 (54%) patients. Rate-control drugs were changed in
2: 2 were started on a regimen of beta-blockers; 9 had
eta-blockers increased; 4 were commenced on digoxin; and
had digoxin increased. By 3 months, 23 of 26 (88%) were
ate controlled. At 12 months, 2 were in sinus rhythm (1
fter defibrillation at 9 months; 1 after undergoing abla-
ion); of the remainder, 23 of 24 (96%) were rate controlled.
atheter ablation. Of 26 patients randomized, 25 under-
ent catheter ablation after 1 withdrew consent. Procedure
uration was 333  61 min; fluoroscopy was 80  19 min;
nd ablation was 82  20 min. All patients had conduction
block of the pulmonary veins and roof; 24 of 25 (96%) had
mitral isthmus block (12 requiring ablation within the
coronary sinus); 22 of 25 (88%) had cavotricuspid isthmus
block (not attempted in 2 due to concern with regard to
prolonged anesthetic).
One patient had asymptomatic flutter at final follow-up
after a single procedure. Another reverted to AF by 6
; ARC-HF  A Randomised Trial to Assess Catheter Ablation Versus Rate Con-
eral anesthesia; ITT  inter-trial interval; LVEF  left ventricular ejectionrillation
 genmonths but declined further ablation, given prior compli-
ular eje
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Ablation Versus Rate Control for AF in HF May 7, 2013:1894–903cations. Five patients had additional ablation procedures for
recurrent arrhythmia during follow-up: 4 for atrial tachy-
cardia, and 1 for AF (followed by a third procedure for atrial
tachycardia). Mean time to first atrial arrhythmia recurrence
was 155 (95% CI: 62 to 248) days. Direct current cardio-
version was required during the blanking period in 8
patients, 3 of whom remained arrhythmia-free.
By intention-to-treat, Kaplan-Meier 1-year arrhythmia-
free survival was 69% after a single ablation, off a regimen of
antiarrhythmic drugs (Fig. 6). Mean arrhythmia-free sur-
vival time was 304 (95% CI: 264 to 345) days. After all
procedures, 22 of 25 (88%) were in sinus rhythm without
further atrial arrhythmias, 1 of whom was on a regimen of
sotalol and amiodarone for ventricular arrhythmias. Single-
procedure success was 72%, and multi-procedural success
Baseline CharacteristicsTable 1 Baseline Characteristics
Age (yrs)
Male
HF etiology
Ischemic
Nonischemic
Coronary atherosclerosis
Time since HF diagnosis (months)
Time since AF diagnosis (months)
Duration of continuous AF (months)
NYHA functional class
II
III
Recent HF hospital stay (1 yr)
Minnesota LHFQ score (/105)
Peak VO2 (ml/kg/min)
Radionuclide LVEF (%)
LA diameter (M-mode, mm)
BNP (pg/ml)
Creatinine
6MW distance (m)
Resting HR (beats/min)
Exercise HR (beats/min)
Rate controlled at baseline (80 rest, 110 at 6MW)
QRS duration (ms), non-paced only
Pre-existing ICD or CRT
CRT
Ventricular pacing dependent
Beta blocker
ACE-I or ARB
Aldosterone antagonist
Amiodarone
Digoxin
1 prior class I/III antiarrhythmic
1 prior electrical cardioversion
Values are mean  SD or n (%).
ACE-I  angiotensin-converting enzyme inhibitor; AF  atrial fibrilla
CRT cardiac resynchronization therapy; HF heart failure; HR he
Minnesota Living with Heart Failure Questionnaire; LVEF  left ventric
6MW  6-min walk.was 92%, excluding the patient who declined ablation.Complications. There was 1 serious procedural complica-
tion: a steam-pop caused tamponade during cavotricuspid-
isthmus ablation, requiring emergency pericardiocentesis
and a sternotomy to repair a perforation at the atrioventric-
ular groove. Other complications were 1 groin hematoma, 1
chest infection 2 weeks post-ablation, and 1 patient with
post-procedural pulmonary edema, which resolved within
24 h. All these patients made a full recovery and completed
follow-up.
Discussion
This is the first randomized clinical trial of ablation-based
rhythm control, versus rate control, for persistent AF in HF
to focus on objective cardiopulmonary exercise capacity. We
ate Control
(n  26)
Catheter Ablation
(n  26) p Value
62 9 64 10 0.38
24 (92) 21 (81) 0.22
7 (27) 10 (38)
19 (73) 16 (62) 0.38
13 (50) 11 (42) 0.58
48 57 68 62 0.22
51 76 51 39 0.98
24 29 23 22 0.95
.50 0.51 2.46 0.51 0.79
13 (50) 14 (54)
13 (50) 12 (46)
7 (27) 10 (38) 0.38
49 21 42 23 0.23
8.2 4.8 16.3 5.3 0.19
25 7 22 8 0.13
46 7 50 6 0.07
283 285 412 324 0.13
102 28 96 24 0.42
411 109 416 78 0.84
81 12 77 9 0.18
109 18 108 15 0.88
14 (54) 17 (65) 0.40
113 21 119 19 0.37
4 (15) 10 (38) 0.06
3 (12) 8 (31) 0.09
1 (4) 1 (4) 1.00
24 (92) 24 (92) 1.00
26 (100) 25 (96) 0.31
6 (23) 13 (50) 0.04
3 (12) 3 (12) 1.00
12 (46) 16 (62) 0.27
9 (36) 9 (36) 1.00
15 (58) 14 (54) 0.78
B  angiotensin receptor blocker; BNP  B-type natriuretic peptide;
; ICD implantable cardioverter defibrillator; LA left atrial; LHFQ
ction fraction; NYHA  New York Heart Association functional class;R
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May 7, 2013:1894–903 Ablation Versus Rate Control for AF in HFprimary endpoint of peak VO2 as well as quality of life and
eurohormonal status. Left atrial size was reduced by
blation, although EF—which has greater natural variability
nd showed overall improvement in both arms—showed
Follow up (months)
2
1
0
1
2
3
4
0 3 12
Figure 2 Primary Endpoint: Summary Data
By intention-to-treat, change () in peak oxygen consumption (VO2) (mean  95% con-
fidence interval) from baseline, comparing ablation (solid dot/line) versus rate control
(open dot and dashed line) at 3- (p  0.38) and 12-month (p  0.018) follow-up. Sta-
tistical significance shown between groups at each time point: *if p  0.05.
Figure 3 Primary Endpoint: Individual Data
Individual patient data for ablation (left) and rate-control (right) showing absolute
Mean and SD for each time point are shown at the bottom.nly a nonsignificant increase. Overall, these results suggest
hat rhythm control by ablation is a more effective strategy
han medical rate control.
Previous studies have found no advantage from drug-based
hythm control over rate control (8,9). The AFFIRM (Atrial
ibrillation Follow-up Investigation of Rhythm Manage-
ent) data showed a trend toward favorability of rhythm
ontrol in those with HF (8), but results from the AF-CHF
Atrial Fibrillation and Congestive Heart Failure) trial
howed no benefit over rate control (7). There is, however,
vidence that sinus rhythm is beneficial, if it can be
aintained (8,24). Although this might reflect self-
election, a role has been argued for a therapy that can
aintain sinus rhythm with minimal long-term side effects.
ecause catheter ablation might be able to achieve this and
ad shown promise in nonrandomized studies in the HF
opulation (12,14), the next step was to prospectively
ompare an ablation-based rhythm-control strategy directly
gainst medical rate control (7) in a well-defined cohort
ith nonparoxysmal AF and systolic HF, which formed the
asis for the ARC-HF (A Randomised Trial to Assess
atheter Ablation Versus Rate Control in the Management
f Persistent Atrial Fibrillation in Chronic Heart Failure).
The primary endpoint, peak VO2, is well-established as a
rognostic indicator in HF (15–17) and as an endpoint in
linical trials (25). Recently Swank et al. (26) have shown
for peak oxygen consumption (VO2) at baseline and 3- and 12-month follow-up.values
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Ablation Versus Rate Control for AF in HF May 7, 2013:1894–903that modest increases in peak VO2 were associated with
reduced mortality and hospital stay. For every 6% in-
crease in VO2 at repeat cardiopulmonary exercise testing
after 3 months, there was a 7% reduction in all-cause
mortality. In our study the overall benefit was approxi-
mately 20% (mean: 19.9% higher than rate control, 95%
CI: 3.9% to 35.9%, p  0.016)—which might have
favorable prognostic implications.
Previous studies have shown that reversion to sinus
rhythm increases peak VO2 and that maintenance of sinus
rhythm leads to later improvement after 1 to 2 years (27). In
our study, it is unlikely that the exercise advantage of
ablation arose solely from being in sinus rhythm during the
exercise test alone, because the same high proportion of
patients were in sinus rhythm at 3 months and 12 months,
yet approximately three-quarters of the 12-month advan-
tage developed only in those intervening 9 months: an
additional increment of 2.55 ml/kg/min (95% CI: 0.71 to
300
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Figure 4 Secondary Endpoints
By intention-to-treat, charts show change () from baseline, displayed as mean 
quartile range (Minnesota Living with Heart Failure Questionnaire [LFHQ] score, 6-m
nonsignificant trend shown between groups at each time point: *if p  0.05, i^f p  0.1.4.39 ml/kg/min, p  0.008). The most likely explanation wor this is progressive systemic improvement in cardiovas-
ular physiology, largely occurring long after sinus rhythm
as restored.
Minnesota LHFQ score and BNP improved in the
blation arm, which became more visible as follow-up
rogressed. The LHFQ score, a validated measure of
herapeutic efficacy, was improved by a magnitude similar to
hat previously associated with favorable prognostic out-
omes (28). The reduction in BNP with ablation, previously
emonstrated in a non-HF population (29), might also have
rognostic implications, particularly because BNP levels
eem not to be independently affected by rhythm itself in
F (30). Our study did not show significant differences in
he 6-min walk distance, but this—being self-paced—is
pen to an additional degree of variation not present on
ardiopulmonary exercise testing, the latter having more
xtensively documented relationship to long-term survival
15–17,31). Although the improvement in EF post-ablation
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Ablatioas consistent with previous studies (10–14,20), some
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May 7, 2013:1894–903 Ablation Versus Rate Control for AF in HFimprovement—perhaps reflecting increased diastolic filling
consequent to lower mean heart rate—was seen in the
rate-control group, and thus overall EF showed only a
numerical trend toward improvement; nevertheless in head-
to-head comparison cardiopulmonary exercise capacity has
stronger prognostic power in HF than in EF (15). Regres-
sion of left atrial dilation occurred post-ablation. Although
this has been observed before and might contribute to
reduced arrhythmia recurrence (32), this is a notable finding
in a HF population where atrial dilation could be less
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Figure 6 Single Procedure Atrial
Arrhythmia-Free Survival at 1 Year
Intention-to-treat Kaplan-Meier atrial arrhythmia-free survival estimation after a
single ablation procedure. The blanking period was set at 2 months, after
which occurrence of documented atrial tachyarrhythmia constituted procedural
failure.reversible. Given time, the atrium has some potential to
recover, despite this advanced substrate.
Maintenance of sinus rhythm was achieved in 92% of
those who underwent ablation, with 72% single-procedure
success, off a regimen of antiarrhythmic medication. The
high success rate might reflect the increasing efficacy of
modern protocols, building upon 50% single-procedure
success as reported in 2004 (12). More recently the PABA-
CHF (Pulmonary Vein Antrum Isolation vs AV Node
Ablation With Biventricular Pacing for Treatment of Atrial
Fibrillation in Patients With Congestive Heart Failure)
study, with one-half the patients having paroxysmal AF,
achieved 71% freedom from AF off drugs regimen at 6
months (20). Our protocol also involved multiple linear
lesions including the cavotricuspid isthmus and ablation of
abnormal electrograms as per contemporary practice (33),
and the inherent long procedure times provided a long
period during which pulmonary-vein reconnections could
be identified and corrected, which might be an additional
avenue that improved outcome (34). Unlike earlier studies
of AF ablation, proven failure of rhythm-control therapy
was not a prerequisite for entry to the ARC-HF trial. Over
one-third of patients had never undergone any attempt to
restore sinus rhythm, and thus the outcomes might reflect a
more amenable AF cohort than historical studies.
Since commencement of the ARC-HF trial, a random-
ized trial with a different ablation protocol that delivered
50% sinus rhythm maintenance and with shorter follow-up
(6 months) (35) reported no significant difference in the
endpoints of EF, N-terminal pro-BNP, and quality of life.
As the investigators commented, this rate of procedural
success reduced power greatly. Additionally, EF might not
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Ablation Versus Rate Control for AF in HF May 7, 2013:1894–903considering the greater prognostic power of integrated
markers such as objective exercise capacity (16). A follow-up
duration of only 6 months might also be insufficient for the
effect of restoration of sinus rhythm to fully manifest. The
ARC-HF trial helps put the Macdonald et al. (35) study in
context: the difference in headline results between the
studies might be not a contradiction but merely a manifes-
tation of the markedly different number of patients required
to detect an effect.
Study limitations. The ARC-HF trial was not designed to
evaluate event endpoints: studies specifically designed to
evaluate the prognostic impact of AF ablation are now
underway and are scheduled to complete in 3 to 4 years,
including the CASTLE-AF (Catheter Ablation Versus
Standard Conventional Treatment in Patients With Left
Ventricular Dysfunction and Atrial Fibrillation) and RAFT
AF (A Randomized Ablation-based Atrial Fibrillation
Rhythm Control Versus Rate Control Trial in Patients
With Heart Failure and High Burden Atrial Fibrillation)
trials. Those larger studies will help provide more informa-
tion about procedural complications, which affected 4 of 25
patients in our study, and also about the longer-term success
of ablation in maintaining sinus rhythm, which is likely to
be lower.
Our cohort was a little younger than those in other
clinical trials in AF and HF (7) and correspondingly had a
lower rate of ischemic etiology, which might limit its
generalizability. However, there were no constraints other
than those listed in the methods; the study was registered
prospectively, and all patients formally enrolled (36). This
study intentionally only addressed patients who had HF
symptoms and therefore is not informative about the po-
tential for benefit in asymptomatic patients. We do not
know the greater denominator beyond the 101 who were
referred to the trial; many patients might have not been
referred because of geography, lack of symptoms, aversion to
invasive procedures, or disinclination to volunteer. Al-
though randomized trials have weaknesses, they remain the
gold standard for evaluating therapeutic choices (37).
No imputation was made for missing data in the primary
analysis to account for the patient who died before final
follow-up: at sensitivity analysis, a worst-case scenario
imputed a peak VO2 value equal to the lowest resting VO2
in any patient, showed resulting mean benefit of catheter
ablation of 2.63 ml/kg/min (95% CI: 0.03 to 5.23
l/kg/min, p  0.048).
We did not attempt to identify post-hoc predictors of
ndividualized response, because this activity is generally
utile and often misleading (36).
There were some minor imbalances in the baseline
haracteristics of patients, to be expected in any randomized
tudy. However, in regression analysis, neither increased
eta-blocker dose under rate control (p  0.66) nor pres-
nce of aldosterone antagonists (p  0.14) or cardiac
esynchronization therapy (p  0.56) at baseline signifi-
antly influenced the primary endpoint.Although the ARC-HF trial complied with the minimal
ECG monitoring for persistent AF ablation recommended
by the international consensus statements of 2007 (22) and
2012 (38), silent episodes of paroxysmal AF might have
been missed during follow-up. However, in this population
with prior persistent AF, the presence of sinus rhythm on
multiple visits is highly suggestive of a major reduction in
arrhythmia burden.
The ideal ablation strategy in persistent AF, particularly if
longstanding, remains unknown. We systematically applied
an extensive ablation strategy in this challenging cohort to
minimize arrhythmia recurrence (39).
Conclusions
The ARC-HF trial, a randomized trial of patients with
persistent AF and HF, indicates that an ablation strategy—
achieving maintenance of sinus rhythm in the majority—
produces improvements within 12 months in symptoms,
neurohormonal status, and objective physiological exercise
capacity. Progressive improvement from 3 to 12 months
implies that the effects reflect more than just sinus rhythm
restoration, suggesting this method of rhythm control ini-
tiates a period of progressive systemic regression of the HF
syndrome. Large-scale trials have commenced to assess the
prognostic impact of catheter ablation-based rhythm-
control of AF in HF: the encouraging pointers for now are
that, under randomized controlled conditions, 2 powerful
objective prognostic markers (VO2 and BNP) respond
avorably.
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